美国信息技术与创新基金会（ITIF）：2024人工智能赋能生物制药行业创新研究报告（中译版）（47页）.pdf

1、 itif.org Harnessing AI to Accelerate Innovation in the Biopharmaceutical Industry SANDRA BARBOSU|NOVEMBER 2024 AI has the potential to transform drug development by enhancing productivity across the entire development pipeline,boosting biopharmaceutical innovation,accelerating the delivery of new t

2、herapies,and fostering competition to help improve public health outcomes.KEY TAKEAWAYS Drug development is a costly,lengthy,and risky process,marked by declining productivity.Bringing a new drug to market can cost billions of dollars and take over a decade,with fewer than 8 percent of early candida

3、tes succeeding.AI has the potential to boost the efficiency of drug development,accelerating the delivery of new therapies and fostering competition,which could improve public health outcomes.AI applications span the entire drug development pipelinefrom speeding up drug discovery and enhancing clini

4、cal trials to streamlining manufacturing and supply chains.For broader,effective adoption of AI in drug development,key challenges such as data quality and availability,potential for algorithmic bias,workflow integration,and regulatory guidelines must be addressed.Key policy elements to advance AI a

5、doption include public funding for basic research,workforce training,support for privacy-enhancing data sharing and access,and a risk-based regulatory framework based on the risk level each AI use may pose to patients.Such policies are essential to unlocking AIs full potential in drug development,en

6、abling faster delivery of potentially life-saving therapies and expanding patient access.INFORMATION TECHNOLOGY&INNOVATION FOUNDATION|NOVEMBER 2024 PAGE 2 CONTENTS Key Takeaways.1 Introduction.3 The Drug Development Process.3 The Role of AI in Drug Development.7 Facilitating Drug Discovery.8 Streaml